ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study

Aysun Aksoy1, Seda Çolak2, Burcu Yagız3, Belkıs Nihan Coşkun4, Ahmet Omma5, Naile Bolca6, Rabia Ergelen7, Haner Direskeneli8 and Fatma Alibaz-Oner1, 1Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 2Rheumatology, Numune Training and Research Hospital, ankara, Turkey, 3Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 4Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 5Numune Training and Research Hospital, ankara, Turkey, 6Radiology, Uludag University, School of Medicine, Bursa, Turkey, 7Marmara University School of Medicine, Radiology, ISTANBUL, Turkey, 8Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Vascular involvement is seen in about one third of patients with Behçet Disease(BD). DVT(deep venous thrombosis) is the most common form of vascular Behçet Disease(VBD).Post-thrombotic syndrome(PTS) developing after a thrombotic event in lower extremity is one of the major complications of DVT and affects negatively patients’quality of life.In this study, we aimed to assess the presence,severity and risk factors of PTS and venous disease spesific quality of life in VBD.

Methods:

This study included 96 patients with BD (Female/Male:18/78, mean age: 38.8±8.74 years) having history of DVT from 3 tertiary Rheumatology centers in Turkey.Villalta scale was used to assess PTS.According to scale;PTS is present if score >4 and degree of PTS mild,moderate and severe if score 5-9,10-14,>14 respectively.The Venous Disability Score(VDS) and the Venous Clinical Severity Score(VCSS) were used for the assessment of venous disease. All patients were assessed with color Doppler ultrasonography(US) by experienced radiologists within 1 weeks following the clinical examination.In each patient, a total of 16superficial and deep veins in both legs were assessed for the presence or absence of obstruction,recanalization,reflux and collaterals.

Results:

When vascular involvement developed, mean age was 32.7±8.65.Venous assessment was done after 6(0-26)years first vascular event.During venous assessment, median disease duration was 9(0-34)years.Eighty(84.2%) patients were under ımmunsupressive(IS) treatment and 13 of these patients were under anticoagulation treatment in addition to ISs. Median IS time 37.5(1-256);anticoagulation time 12(1-156)months. PTS was present in 57(61.3%) out of 93 patients and severe PTS was present in 19(19.8%)patients.There was no association between presence of PTS and sex, age during DVT, compression stocking tretament usage, presence of relaps, duration of trombosis.There was no difference between patients with or without anticoagulant usage regarding PTS presence (p=0.817) and also there is no difference at duration of IS and AC treatment between patients with or without PTS .Doppler US examination shows no abnormalities at 10 (10.6%) patients, 5(50%)of these patients had PTS. Bilateral leg vessel involvement was present in 31(31.4%)patients.Fourty(47.6%) patients had both upper and lower leg vessel involvement.But we didn’t find any associaton with PTS presence and doppler US findings such as bilateral involvement, upper and lower leg vessel involvement, reflux or trombosis at any vessel in the affected leg.

When VBD patients with and without PTS were compared, quality of life(VEINES-QoL/Sym) and VCSS were significantly worse. The Behçet Syndrome Activity Score was also significantly higher in patients with PTS

Conclusion:

We found that PTS develops in more than half of the patients with VBD during follow-up. We didn’t found any predictor factor for development of PTS.About one third of patient with PTS were severe PTS.Our results confirm that PTS is very frequent clinical problem for physicians treating VBD in daily practice.During management of patients with VBD, PTS should be taken into account as much as preventing vascular relapses.


Disclosure: A. Aksoy, None; S. Çolak, None; B. Yagız, None; B. N. Coşkun, None; A. Omma, None; N. Bolca, None; R. Ergelen, None; H. Direskeneli, None; F. Alibaz-Oner, None.

To cite this abstract in AMA style:

Aksoy A, Çolak S, Yagız B, Coşkun BN, Omma A, Bolca N, Ergelen R, Direskeneli H, Alibaz-Oner F. Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/assessment-of-severity-and-risk-factors-of-post-thrombotic-syndrome-in-vascular-behcet-disease-muticentered-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-severity-and-risk-factors-of-post-thrombotic-syndrome-in-vascular-behcet-disease-muticentered-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology